# Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer

> **NCT00101842** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 61 (—)

## Conditions studied

- Carcinoma, Transitional Cell

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Gemcitabine
- **DRUG:** Platinol

## Key facts

- **NCT ID:** NCT00101842
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** —
- **Final completion:** 2006-07
- **Target enrollment:** 61 (—)
- **Last updated:** 2006-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00101842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00101842, "Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00101842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*